Overview

Rayzebio IIT Study of Dotatate in Breast Cancer

Status:
Recruiting

Trial end date:
2023-07-31

Target enrollment:

Participant gender:

Summary

This will be a Phase 2 clinical trial to assess somatostatin receptor (SSTR) expression in Stage IV estrogen receptor positive (ER+) breast cancer using Ga-68-DOTATATE PET/CT.

Phase:

Phase 2

Details

Lead Sponsor:

Hoag Memorial Hospital Presbyterian

Collaborator:

RayzeBio, Inc.